A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects With Active Eosinophilic Esophagitis
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Cendakimab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 08 Aug 2023 Planned primary completion date changed from 5 Dec 2023 to 27 Dec 2023.
- 08 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Jul 2023 Planned End Date changed from 28 Jan 2025 to 2 Oct 2024.